Crispr Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Piper Jaffray Companies raised their Q1 2020 earnings per share estimates for shares of Crispr Therapeutics in a research report issued on Tuesday, November 26th, according to Zacks Investment Research. Piper Jaffray Companies analyst E. Tenthoff now forecasts that the company will earn ($1.20) per share for the quarter, up from their prior estimate of ($1.29). Piper Jaffray Companies currently has a “Buy” rating and a $104.00 target price on the stock. Piper Jaffray Companies also issued estimates for Crispr Therapeutics’ Q2 2020 earnings at ($1.30) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.49) EPS, FY2020 earnings at ($5.38) EPS, Q1 2021 earnings at ($1.65) EPS, Q2 2021 earnings at ($1.81) EPS, Q3 2021 earnings at ($1.88) EPS and FY2021 earnings at ($7.38) EPS.

Several other analysts have also recently weighed in on CRSP. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Friday. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Oppenheimer lifted their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Goldman Sachs Group boosted their price target on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Finally, Chardan Capital restated a “buy” rating and set a $72.50 price objective on shares of Crispr Therapeutics in a research note on Monday, November 18th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $69.54.

CRSP opened at $72.37 on Thursday. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The company has a market capitalization of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30. The stock has a fifty day moving average of $54.81 and a 200-day moving average of $47.38. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

In other news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total transaction of $412,500.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock worth $3,620,760 in the last quarter. 21.40% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. lifted its holdings in shares of Crispr Therapeutics by 324.3% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Crispr Therapeutics by 34.7% in the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares in the last quarter. Orbimed Advisors LLC bought a new stake in shares of Crispr Therapeutics during the 3rd quarter valued at approximately $21,167,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares in the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: What is a CD ladder?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link